Sanofi Pasteur and MSD to end joint vaccines operations in Europe

Sanofi Pasteur and MSD have confirmed that their joint vaccines operations in Europe are to end.

The two organisations plan to integrate their respective vaccine businesses into their existing operations, so they can pursue distinct growth strategies across the continent.

The joint venture has been operating for more than two decades and according to Sanofi Pasteur and MSD, it has achieved "considerable success" during this time from both a commercial and public health perspective.

However, they said in a joint statement that after carefully considering their individual strategic priorities, as well as the economic and regulatory environments for vaccine operations in the European Union, it has been mutually agreed that managing their product portfolios independently is in their best interests.

"We believe that focusing our efforts on opportunities unique to our respective companies will better position us to drive growth, execute in a more efficient manner and optimise vaccine coverage," the companies added.